GlassScriptPhysician profile
Ashley Majoskey
NPI 1043561517
$4,130.74
in general payments reported to CMS, 2019-2025
27 companies · $571 in 2025
The $571 reported for 2025 was more than what 82% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,014 · 2022: $1,163 · 2023: $351 · 2024: $31.62 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $853 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $853.48 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $821.61 | 2021-2023 | Breztri, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $717.23 | 2021-2023 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $403.82 | 2021-2023 | Ofev |
| Glaxosmithkline, LLC. | $366.46 | 2021-2023 | Nucala |
| Inspire Medical Systems, INC. | $297.46 | 2025 | Inspire |
| Mylan Specialty L.P. | $240.84 | 2021 | |
| Janssen Pharmaceuticals, INC | $157.40 | 2021 | |
| Verona Pharma, INC. | $135.08 | 2025 | Ohtuvayre |
| Amgen INC. | $125.86 | 2021 | |
| Harmony Biosciences LLC | $115.21 | 2023-2025 | Wakix |
| Teva Pharmaceuticals USA, INC. | $82.27 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.99 | 2021 | |
| Merck Sharp & Dohme LLC | $80.44 | 2021 | |
| Baxter Healthcare | $66.34 | 2022-2023 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Amarin Pharma, INC. | $64.35 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $53.47 | 2022 | |
| Jazz Pharmaceuticals INC. | $50.18 | 2021 | |
| Genzyme Corporation | $48.04 | 2021-2022 | |
| Pulmonx Corporation | $43.22 | 2024-2025 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Pfizer INC. | $35.08 | 2021 | |
| Novartis Pharmaceuticals Corporation | $34.58 | 2021 | |
| Gilead Sciences, INC. | $29.61 | 2022-2023 | Veklury |
| Axsome Therapeutics, INC. | $23.29 | 2022 | |
| Insmed, INC. | $15.54 | 2021 | |
| Grifols USA, LLC | $15.45 | 2024 | Prolastin-C Liquid |
| Abbvie INC. | $14.36 | 2022 | |
| 3b Medical, INC. | $11.56 | 2025 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Majoskey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.